A Multicenter, Open-label, Single-arm, Phase 4 Study to Evaluate the Efficacy and Safety of Filgotinib in Korean Patients With Rheumatoid Arthritis
Latest Information Update: 06 Dec 2024
Price :
$35 *
At a glance
- Drugs Filgotinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Eisai Korea
- 02 Dec 2024 Status changed from not yet recruiting to recruiting.
- 08 Oct 2024 New trial record